QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.005421v1 33/11/1679    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taub, M. E. Articles by Almeida, I. Search for Related Content PubMed PubMed Citation Articles by Taub, M. E. Articles by Almeida, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB COLCHICINE DEXAMETHASONE DIGOXIN HYDROCORTISONE PROBENECID TAXOL VINBLASTINE

FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY

Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

Compounds known to modulate P-glycoprotein (P-gp) activity were evaluated in cell monolayers expressing P-gp for their effects on the secretory transport of P-gp substrates paclitaxel, vinblastine, and digoxin. Paclitaxel has been proposed to selectively interact with a binding site on P-gp that is distinct from the vinblastine and digoxin-binding site. Using Madin-Darby canine kidney (MDCK)-multidrug resistance-1 (MDR1), MDCK-wild-type (WT), and Caco-2 cell monolayers, the basal-to-apical (BL-AP) apparent permeability (P_app) of [³H]paclitaxel, [³H]vinblastine, and [³H]digoxin in the presence of various concentrations of a series of structurally diverse P-gp substrates and modulators of P-gp function were determined. MDCK-WT cell monolayers demonstrated active secretory transport of all P-gp substrate probes, although the sensitivity to inhibition by verapamil was lower than that demonstrated in MDCK-MDR1 cell monolayers. When evaluated as competitive inhibitors, several known P-gp substrates had no effect or only a slight modulatory effect on the BL-AP P_app of all probe substrates in MDCK-MDR1 cells. The secretory transport of P-gp substrates in MDCK-WT cells was more sensitive to inhibition by known P-gp modulators compared with MDCK-MDR1 cells. Low concentrations of ketoconazole (1–3 µM) activated the BL-AP P_app of [³H]vinblastine and [³H]digoxin in MDCK-MDR1 cells but not in MDCK-WT or Caco-2 cells. Determination of secretory transport in P-gp expressing cell monolayers, such as MDCK-MDR1 and Caco-2, may be complicated by substrate cooperativity and allosteric binding, which may result in the activation of P-gp. In addition, expression of other efflux transporters in these cell lines introduces additional complexity in distinguishing which transporter is responsible for substrate recognition and transport.

This article has been cited by other articles:

				A. A. Othman, S. A. Syed, A. H. Newman, and N. D. Eddington Transport, Metabolism, and in Vivo Population Pharmacokinetics of the Chloro Benztropine Analogs, a Class of Compounds Extensively Evaluated in Animal Models of Drug Abuse J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 344 - 353. [Abstract] [Full Text] [PDF]

				C. Chang, P. M. Bahadduri, J. E. Polli, P. W. Swaan, and S. Ekins Rapid Identification of P-glycoprotein Substrates and Inhibitors Drug Metab. Dispos., December 1, 2006; 34(12): 1976 - 1984. [Abstract] [Full Text] [PDF]

				P. Abidi, W. Chen, F. B. Kraemer, H. Li, and J. Liu The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms J. Lipid Res., October 1, 2006; 47(10): 2134 - 2147. [Abstract] [Full Text] [PDF]

				A. Azzariti, N. A. Colabufo, F. Berardi, L. Porcelli, M. Niso, G. M. Simone, R. Perrone, and A. Paradiso Cyclohexylpiperazine derivative PB28, a {sigma}2 agonist and {sigma}1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther., July 1, 2006; 5(7): 1807 - 1816. [Abstract] [Full Text] [PDF]

				J. Rautio, J. E. Humphreys, L. O. Webster, A. Balakrishnan, J. P. Keogh, J. R. Kunta, C. J. Serabjit-Singh, and J. W. Polli IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES Drug Metab. Dispos., May 1, 2006; 34(5): 786 - 792. [Abstract] [Full Text] [PDF]